Parallel Advisors’s Pacific Biosciences PACB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.09K | Buy |
3,101
+101
| +3% | +$181 | ﹤0.01% | 3112 |
|
|
2025
Q4 | $5.61K | Hold |
3,000
| – | – | ﹤0.01% | 2807 |
|
|
2025
Q3 | $3.84K | Hold |
3,000
| – | – | ﹤0.01% | 2879 |
|
|
2025
Q2 | $3.72K | Sell |
3,000
-730
| -20% | -$843 | ﹤0.01% | 2844 |
|
|
2025
Q1 | $4.4K | Buy |
3,730
+466
| +14% | +$715 | ﹤0.01% | 2723 |
|
|
2024
Q4 | $5.97K | Hold |
3,264
| – | – | ﹤0.01% | 2574 |
|
|
2024
Q3 | $5.55K | Buy |
3,264
+264
| +9% | +$434 | ﹤0.01% | 2581 |
|
|
2024
Q2 | $4.11K | Hold |
3,000
| – | – | ﹤0.01% | 2593 |
|
|
2024
Q1 | $11.3K | Buy |
+3,000
| New | +$17.6K | ﹤0.01% | 2254 |
|
|
2023
Q4 | – | Sell |
-46
| Closed | -$384 | – | 3432 |
|
|
2023
Q3 | $384 | Hold |
46
| – | – | ﹤0.01% | 3152 |
|
|
2023
Q2 | $612 | Hold |
46
| – | – | ﹤0.01% | 3057 |
|
|
2023
Q1 | $533 | Hold |
46
| – | – | ﹤0.01% | 3106 |
|
|
2022
Q4 | $376 | Hold |
46
| – | – | ﹤0.01% | 3088 |
|
|
2022
Q3 | $0 | Hold |
46
| – | – | ﹤0.01% | 3397 |
|
|
2022
Q2 | $0 | Sell |
46
-13
| -22% | -$79 | ﹤0.01% | 3256 |
|
|
2022
Q1 | $1K | Sell |
59
-44
| -43% | -$507 | ﹤0.01% | 2803 |
|
|
2021
Q4 | $2K | Buy |
103
+89
| +636% | +$2.15K | ﹤0.01% | 2738 |
|
|
2021
Q3 | $0 | Sell |
14
-20
| -59% | -$593 | ﹤0.01% | 3216 |
|
|
2021
Q2 | $1K | Buy |
34
+25
| +278% | +$727 | ﹤0.01% | 2792 |
|
|
2021
Q1 | $0 | Buy |
+9
| New | +$315 | ﹤0.01% | 2870 |
|
|
2020
Q4 | – | Sell |
-712
| Closed | -$7K | – | 2676 |
|
|
2020
Q3 | $7K | Sell |
712
-266
| -27% | -$1.53K | ﹤0.01% | 1903 |
|
|
2020
Q2 | $3K | Buy |
978
+446
| +84% | +$1.52K | ﹤0.01% | 2114 |
|
|
2020
Q1 | $1K | Sell |
532
-10,108
| -95% | -$41.4K | ﹤0.01% | 2311 |
|
|
2019
Q4 | $55K | Buy |
10,640
+7,111
| +202% | +$36.1K | ﹤0.01% | 1003 |
|
|
2019
Q3 | $18K | Buy |
3,529
+1,498
| +74% | +$8.38K | ﹤0.01% | 1408 |
|
|
2019
Q2 | $12K | Buy |
2,031
+1,499
| +282% | +$10.5K | ﹤0.01% | 1513 |
|
|
2019
Q1 | $4K | Hold |
532
| – | – | ﹤0.01% | 1882 |
|
|
2018
Q4 | $3K | Hold |
532
| – | – | ﹤0.01% | 1762 |
|
|
2018
Q3 | $3K | Hold |
532
| – | – | ﹤0.01% | 1924 |
|
|
2018
Q2 | $1K | Hold |
532
| – | – | ﹤0.01% | 1997 |
|
|
2018
Q1 | $1K | Buy |
+532
| New | +$1.38K | ﹤0.01% | 1997 |
|
Other funds holding PACB
AIM
VCM
NAMA
Parallel Advisors's PACB Position: Q1 2026 in Review
Parallel Advisors increased its Pacific Biosciences (PACB) stake by 3.4% in Q1 2026, buying an estimated $181 and bringing the position to 3,101 shares worth $4.09K. The position accounts for ﹤0.01% of the portfolio, ranked #3112.
Parallel Advisors first reported a position in PACB in Q1 2018 and has held it in 31 quarters since. The position peaked at $55K in Q4 2019. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.
- Parallel Advisors held 3,101 shares of Pacific Biosciences worth $4.09K as of Q1 2026.
- Parallel Advisors bought 101 Pacific Biosciences shares in Q1 2026, an estimated $181.
- Pacific Biosciences made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #3112 holding.
- Parallel Advisors first reported a position in Pacific Biosciences in Q1 2018 and has held it in 31 quarters since.
- Parallel Advisors's Pacific Biosciences position peaked at $55K in Q4 2019.
- 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.
Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.